<DOC>
	<DOCNO>NCT00235235</DOCNO>
	<brief_summary>The propose trial provide unique opportunity combine genomic , proteomic , pharmacogenomic assessment patient receive commonly use chemotherapy advance breast cancer . To date trial analyze gene protein expression time point patient , combined clinical outcome . Similar previous attempt predict response base expression single gene protein , researcher expect neither genomic proteomic profile alone sufficient optimize therapy . Rather , researcher expect iterative process combine information glean platform , modify avoid toxicity base pharmacogenomics .</brief_summary>
	<brief_title>A Correlative Study Predicting Response Toxicity Patients Receiving Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This 4 arm , multi-center study . Sample Collection : - Core Biopsy - Serum - Urine Treatment Regimens ( Investigator/Patient Discretion ) : - Arm A : Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 1 every 21-day cycle - Arm B : Capecitabine 1000 mg/m2 BID day 1-14 every 21-day cycle - Arm C : Vinorelbine 25 mg/m2 day 1 , 8 , 15 every 28-day cycle - Arm D : Gemcitabine 1000 mg/m2 day 1 , 8 , 15 every 28-day cycle Performance status &amp; Organ Function : Performance status organ function appropriate chemotherapy opinion treat investigator accord Good Clinical Practice ( GCP ) . Life Expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : Not specify Pulmonary : Not specify</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast locally advance metastatic disease . Disease amenable pretreatment core incisional biopsy adequate tissue histology genomic/proteomic analysis . Measurable disease assess within 21 day prior register protocol therapy RECIST . Planned chemotherapy one follow regimen : 1 . Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 1 every 21day cycle 2 . Capecitabine 1000 mg/m2 BID day 114 every 21day cycle 3 . Vinorelbine 25 mg/m2 day 1 , 8 , 15 every 28day cycle 4 . Gemcitabine 1000 mg/m2 day 1 , 8 , 15 every 28day cycle No serious uncontrolled medical surgical condition investigator feel might compromise study participation . Negative pregnancy test obtain within 7 day prior register protocol therapy woman child bear potential . Unwillingness use adequate contraception ( practice complete abstinence ) . Subjects advise adequate contraception ( complete abstinence ) must continue treatment period 3 month final dose chemotherapy . No breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>